Androgen Receptor Inhibition in CRPC

Evolving Standard of Care for mHSPC Prompts Interest in Deescalation

Che-Kai Tsao, MD, MS, discusses new approaches that could change the standard of care for metastatic hormone-sensitive prostate cancer.

CBR Polling Shows Rapid Uptake of Darolutamide in mHSPC

Recent polling shows oncologists' changing inclination in treatment for metastatic hormone-sensitive prostate cancer (mHSPC) based on tolerability profiles.

Disease Factors Can Support Intensification or Deescalation in HSPC

Che-Kai Tsao, MD, MS, discusses the current state of treatment for metastatic hormone-sensitive prostate cancer.

Rates of Drug Interactions Differentiate ARPIs for Treating mHSPC

During a live event, Cora N. Sternberg, MD, discussed tolerability outcomes from the ARANOTE trial and distinguishing aspects of androgen receptor pathway inhibitors.

Considering the Evolution of ARPI Combination Therapy in mHSPC

During a live event, Cora N. Sternberg, MD, discussed the development of androgen receptor pathway inhibitors and takeaways from the ARANOTE trial in hormone-sensitive prostate cancer.

Navigating ARANOTE Trial Findings and Insurance for Prostate Cancer

During a live event, Tian Zhang, MD, MHS, discussed darolutamide in mHSPC, with efficacy and cost being key considerations for treatment selection.

Applying Recent Trial Data to mHSPC Clinical Decision-Making

During a live event, Tian Zhang, MD, MHS, discussed options and recent trial data for treating metastatic hormone-sensitive prostate cancer.

Analyzing Benefits and Safety of Darolutamide in mHSPC

During a live event, Jahan Aghalar, MD, discussed the efficacy and safety of darolutamide plus ADT in mHSPC in the ARANOTE trial.

Understanding ARPIs to Make Therapy Selection in Prostate Cancer

Pedro C. Barata, MD, MSc, discusses the advantages and disadvantages of darolutamide in metastatic hormone-sensitive prostate cancer.

Considering the Treatment of mHSPC with Oral Therapies

During a live event, Jahan Aghalar, MD, discussed key NCCN-recommended oral therapies and landmark trials for metastatic prostate cancer.

Walking Through the First 3 Physician Visits for Patients with mHSPC

Pedro C. Barata, MD, MSc, discusses a typical process for an oncologist to patients who are newly diagnosed with metastatic hormone-sensitive prostate cancer.

Impact of Newer ARPIs Is Significant in Patients With mHSPC

Pedro C. Barata, MD, MSc, discusses options for metastatic hormone-sensitive prostate cancer in the community setting.

Understanding Why Darolutamide Stands Out Among ARPIs for mHSPC

Pedro C. Barata, MD, MSc, discusses the use of darolutamide in patients with hormone-sensitive prostate cancer.

mHSPC Regimens Are Distinguished by Drug Interactions and Disease Volume

In a live event, Ganesh V. Raj, MD, PhD, discussed the drug-drug interactions and outcomes by disease volumes across ARPI trials in mHSPC.

ARANOTE Trial Aligns With Prior ARPI Plus ADT Studies in mHSPC

In a live event, Ganesh V. Raj, MD, PhD, discussed the landscape of metastatic hormone-sensitive prostate cancer considering the recent data from the ARANOTE study.

ARANOTE Features Significant rPFS Benefit of Darolutamide/ADT in mHSPC

In a live event, Vinay Minocha, MD, discusses the addition of darolutamide to androgen deprivation therapy for in patients with metastatic hormone-sensitive prostate cancer.

Part 2: Factors for Selecting a Novel Hormonal Therapy for nmCRPC

During a live virtual event, Evan Yu, MD, discussed the choice of novel hormonal agent for a patient with nonmetastatic castration-resistant prostate cancer.

Part 1: Deciding Whether Next-Generation Scans Are Needed for nmCRPC

During a live event, Evan Yu, MD, discussed how to monitor a patient being treated with androgen deprivation therapy and hormonal agents for nonmetastatic castration-resistant prostate cancer using prostate-specific antigen levels and next-generation imaging.

Part 3: Trials Show Efficacy of Enzalutamide and Darolutamide For CRPC

During a live virtual event, Eleni Efstathiou, MD, PhD, discussed the phase 3 PROSPER trial of enzalutamide and the phase 3 ARAMIS trial of darolutamide in patients with castration-resistant prostate cancer.

Part 2: SPARTAN Trial Shows Efficacy of Apalutamide for CRPC

During a live virtual event, Eleni Efstathiou, MD, PhD, discussed the phase 3 SPARTAN trial of apalutamide in patients with castration-resistant prostate cancer.

Part 1: Guidelines and Recommendations for Treating nmCRPC

During a live virtual event, Eleni Efstathiou, MD, PhD, discussed the recommended approach to front-line treatment of castration-resistant prostate cancer.

Part 3: Combining Therapies to Treat a Patient With CRPC

During a live virtual event, Alicia Morgans, MD, MPH, discussed when to combine novel hormonal agents with androgen-deprivation therapy in nonmetastatic castrate-resistant prostate cancer and how novel imaging techniques could influence treatment.

Part 2: Concerns When Selecting a Novel Hormonal Agent for CRPC

During a live virtual event, Alicia Morgans, MD, MPH, discussed the choice of novel hormonal agents to combine with androgen-deprivation therapy in nonmetastatic castrate-resistant prostate cancer.

Part 1: The Role and Availability of Germline Testing and PSMA Scans in nmCRPC

During a live virtual event, Alicia Morgans, MD, MPH, discusses the appropriate usage of new genetic testing and PSMA scans in nonmetastatic castration-resistant prostate cancer.

Part 4: Discussing the Use of PET Scans and Metastatic Disease in CRPC

Tanya Dorff, MD, asks the participants of a roundtable discussion about their opinion survival data of androgen receptor–targeted therapy and treating patients with PET scan-only metastatic castration-resistant prostate cancer.

Part 3: Deciding on CRPC Therapy Based on Patient Case and Past Experience

Tanya Dorff, MD, asks the participants of a roundtable discussion which novel hormonal therapy they would choose in a patient with nonmetastatic castration-resistant prostate cancer.

Part 2: Later-Line Therapy in nmCRPC Post Androgen Deprivation Therapy

Tanya Dorff, MD, asks the participants of a roundtable discussion what they would recommend as next-line therapy for a patient with nonmetastatic castration-resistant prostate cancer.

Part 1: Discussing When to Test and Image a Patient With nmCRPC

Tanya Dorff, MD, asks the participants of a roundtable discussion if they would order germline testing and molecular imaging in a patient with nonmetastatic castration-resistant prostate cancer.

Srinivas Reviews Data of Hormonal Agents in the nmCRPC Setting

During a virtual live event with other physicians, Sandy Srinivas, MD, reviewed data for 3 antiandrogens used for patients with nonmetastatic castration-resistant prostate cancer, including apalutamide, darolutamide, and enzalutamide.

Part 4: The Deciding Factors When Picking Between nmCRPC Therapies

In a roundtable discussion with multiple participants, Alicia K. Morgans, MD, MPH, discusses PSA doubling time and participant experience with androgen receptor inhibitors in castration-resistant prostate cancer.

Part 3: Choosing a Novel Hormonal Agent in CRPC

In a roundtable discussion with multiple participants, Alicia K. Morgans, MD, MPH, reviews the options for a patient with castration-resistant prostate cancer who progressed on front-line therapy.

Part 2: The Role of PSMA PET Scans in CRPC

In a roundtable discussion with multiple participants, Alicia K. Morgans, MD, MPH, covers prostate-specific membrane antigen and Axumin testing in castration-resistant prostate cancer.

Part 1: Germline Testing and Molecular Imaging in CRPC

In a roundtable discussion with multiple participants, Alicia K. Morgans, MD, MPH, leads a conversation on germline testing and molecular imaging in castration-resistant prostate cancer.